Photo: Igor Golovniov/SOPA Images/LightRocket via Getty Images

Pharmaceutical company Eli Lilly made its first offer to buy Loxo Oncology on Dec. 20, 2018, and it was eager to close the deal before the J.P. Morgan Healthcare Conference last week, according to new regulatory documents filed by Loxo.

Between the lines: Acquisitions usually take several months of negotiations, not 2 weeks, but both sides in this $8 billion deal moved extraordinarily quickly in part to make a big splash at the health care industry's signature event.

Details: Eli Lilly and Loxo had been in touch since April 2018, but acquisition talks did not begin until last month.

  • Loxo has one FDA-approved drug on the market, but Eli Lilly appeared to be most interested in LOXO-292 — a cancer drug that had "positive interim data" in early clinical trials and received "breakthrough" status from the FDA in September.
  • Loxo did not pursue any other offers, and Eli Lilly only revised its offer once — from the initial $230 per share to the final $235 per share. Loxo's board said Eli Lilly's deal outweighed "the risks of outreach to third parties," according to the filing.
  • Josh Bilenker — an oncologist who used to work at the FDA, is Loxo's CEO and is an operating partner at the private equity firm Aisling Capital, which owns a large chunk of Loxo — will make $45 million from the shares he owns once the deal closes, according to the documents. Bilenker will make another $241 million from the deal based on his vested and unvested stock options.
  • Loxo expects revenue of all of its cancer medicines will peak in 2031 at $2 billion with a 43% profit margin, assuming FDA approvals.

Go deeper

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 10 a.m. ET: 19,412,292 — Total deaths: 722,066 — Total recoveries — 11,773,112Map.
  2. U.S.: Total confirmed cases as of 10 a.m. ET: 4,945,795 — Total deaths: 161,456 — Total recoveries: 1,623,870 — Total tests: 60,415,558Map.
  3. Politics: Trump says he's prepared to sign executive orders on coronavirus aid.
  4. Public health: Fauci says chances are "not great" that COVID-19 vaccine will be 98% effective
  5. Science: Indoor air is the next coronavirus frontline.
  6. World: Africa records over 1 million coronavirus cases — Gates Foundation puts $150 million behind coronavirus vaccine production.
2 hours ago - Health

Indoor air is the next coronavirus frontline

Illustration: Eniola Odetunde/Axios

A growing body of research has made it clear that airborne transmission of the coronavirus is possible.

Why it matters: That fact means indoor spaces can become hot spots. Those spaces also happen to be where most business and schooling takes place, so any hope for a return to normality will require better ways of filtering indoor air.

The silver linings of online school

Illustration: Annelise Capossela/Axios

Online learning can be frustrating for students, teachers and parents, but some methods are working.

The big picture: Just as companies are using this era of telework to try new things, some principals, teachers and education startups are treating remote learning as a period of experimentation, too.